Study Title: A Phase 2 Open Label Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination with Ruxolitinib in Subjects with Myelofibrosis (REFINE)
This trial is closed to accrual. For general questions, please contact the Clinical Trials Office.